Cefixime Clinical Trial

Recruiting now · Phase 3

Conditions studied: Syphilis, Human Immunodeficiency Virus

In brief

This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.

Key facts

Study ID

NCT04958122

Run by

University of Southern California

People needed

400

Starts

2021-06-20

Expected to finish

2027-06-30

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
• 18 years of age or older
• Able to provide informed consent
• Individuals with HIV infection must be on treatment for HIV infection and virologically suppressed (viral load <200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 according to most recent labs before study enrollment

You may not qualify if…

• Pregnancy or a positive pregnancy test on the day of enrollment
• Patients showing signs and symptoms of neurosyphilis
• Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater
• Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, doxycycline, ceftriaxone, or other beta-lactam antibiotics (e.g. amoxicillin)
• Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test
• Self-reported allergy to cephalosporins or penicillin
• Unwilling or unable to attend follow-up visits

Where it is running

• University of Southern California — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.